Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Horizon | Bear case (−1σ) | Base case | Bull case (+1σ) |
|---|---|---|---|
| 1 Month | $6.01 (-18.6%) | $7.38 | $9.07 (+22.9%) |
| 3 Months | $5.16 (-30.0%) | $7.38 | $10.55 (+42.9%) |
| 6 Months | $4.45 (-39.6%) | $7.38 | $12.23 (+65.7%) |
| 12 Months | $3.61 (-51.0%) | $7.38 | $15.07 (+104.2%) |